Tango Therapeutics director granted RSUs, options
Tango Therapeutics director Robert Azelby reported equity awards from the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Tango Therapeutics director Robert Azelby reported equity awards from the company. He received 5,740 shares of Common Stock in the form of restricted stock units (RSUs), with each RSU representing one future share.
The RSUs will vest in three substantially equal annual installments following the grant date, as long as he remains in continuous service. He was also granted a stock option covering 35,910 shares of Common Stock at an exercise price of $27.97 per share. This option vests in 36 substantially equal monthly installments over three years, subject to continued service, and expires on June 19, 2036. These are compensation-related grants, not open‑market purchases.
Insider Trade Summary
Grant/Award: 41,650 shares
Grant/Award
2 txns
Insider
Azelby Robert
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 35,910 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 5,740 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 35,910 contracts (Direct);
Common Stock — 5,740 shares (Direct)
Footnotes (2)
- F1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
- F2. This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Key Figures
RSU grant: 5,740 shares
Option grant size: 35,910 shares
Option exercise price: $27.97 per share
+3 more
6 metrics
RSU grant
5,740 shares
Restricted stock units awarded to director as of June 19, 2026
Option grant size
35,910 shares
Stock option covering Common Stock granted to director
Option exercise price
$27.97 per share
Exercise price for 35,910-share stock option
Option expiration
June 19, 2036
Expiration date of stock option grant
RSUs after grant
5,740 shares
Total Common Stock represented by RSUs following transaction
Options after grant
35,910 options
Total stock options held from this grant following transaction
Key Terms
restricted stock units, Stock Option (Right to Buy), vest, exercise price, +1 more
5 terms
restricted stock units financial
"These shares are represented by restricted stock units (the "RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of $27.9700."
vest financial
"The RSUs will vest in three substantially equal annual installments following the grant date."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price": "27.9700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-06-19T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tango Therapeutics (TNGX) director Robert Azelby receive in this Form 4?
Robert Azelby received equity compensation from Tango Therapeutics, including 5,740 restricted stock units and a stock option for 35,910 shares. These awards are grants from the company, not open-market purchases, and are tied to his ongoing service as a director.
How do the 5,740 RSUs granted to Tango Therapeutics (TNGX) director vest?
The 5,740 RSUs vest in three substantially equal annual installments after the grant date. Each vesting installment requires Robert Azelby to remain in continuous service with Tango Therapeutics through the applicable vesting date to receive the underlying Common Stock shares.
Is the Tango Therapeutics (TNGX) Form 4 for a stock purchase or a compensation grant?
The Form 4 reflects compensation-related equity grants, not an open-market stock purchase. Robert Azelby received RSUs and a stock option as awards from Tango Therapeutics, with vesting schedules tied to his continued service rather than immediate cash transactions in the market.
What is the exercise price and expiration date of the Tango Therapeutics (TNGX) option grant?
The option granted to Robert Azelby has an exercise price of $27.97 per share and an expiration date of June 19, 2036. He may exercise vested portions before expiration, subject to plan terms and his continued service with Tango Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates